Centogene, Alnylam Pharmaceuticals Partner on Biomarker Study of Transthyretin Amyloidosis
The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene.
Alnylam, 23andMe Partner on Free Family Testing Program for Hereditary ATTR Amyloidosis
23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.
Invitae, Alnylam to Provide Free Genetic Testing for Primary Hyperoxaluria
Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.
Alnylam Expands Genetic Testing Program
The company will now offer free genetic testing to patients at risk for acute hepatic porphyrias, a class of diseases for which it is developing a treatment.
Invitae, Alnylam to Provide Free Genetic Testing for Rare Amyloidosis Condition
Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it.